CN114502194A - 用于治疗乙型肝炎病毒感染的组合物和方法 - Google Patents

用于治疗乙型肝炎病毒感染的组合物和方法 Download PDF

Info

Publication number
CN114502194A
CN114502194A CN202080069643.5A CN202080069643A CN114502194A CN 114502194 A CN114502194 A CN 114502194A CN 202080069643 A CN202080069643 A CN 202080069643A CN 114502194 A CN114502194 A CN 114502194A
Authority
CN
China
Prior art keywords
arm region
nucleic acid
uuuuuuuuuu
hbv
cccdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069643.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·小加勒
S·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN114502194A publication Critical patent/CN114502194A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080069643.5A 2019-10-02 2020-09-30 用于治疗乙型肝炎病毒感染的组合物和方法 Pending CN114502194A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909321P 2019-10-02 2019-10-02
US62/909,321 2019-10-02
PCT/US2020/053606 WO2021067480A1 (en) 2019-10-02 2020-09-30 Compositions and methods for treatment of hepatitis b virus infection

Publications (1)

Publication Number Publication Date
CN114502194A true CN114502194A (zh) 2022-05-13

Family

ID=75337516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069643.5A Pending CN114502194A (zh) 2019-10-02 2020-09-30 用于治疗乙型肝炎病毒感染的组合物和方法

Country Status (5)

Country Link
US (1) US20220241314A1 (https=)
EP (1) EP4037706A4 (https=)
JP (1) JP2022550454A (https=)
CN (1) CN114502194A (https=)
WO (1) WO2021067480A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
WO2021226129A1 (en) * 2020-05-04 2021-11-11 Neuralexo, Inc. Small molecule activators of interferon regulatory factor 3 and methods of use thereof
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291534A1 (en) * 2012-11-08 2015-10-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for treating hiv and methods for using the compounds
CN106456615A (zh) * 2014-05-09 2017-02-22 奇尼塔公司 抗病毒化合物、医药组合物及其使用方法
US20180104325A1 (en) * 2013-07-09 2018-04-19 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling
WO2018222910A1 (en) * 2017-05-31 2018-12-06 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013267209B2 (en) * 2012-06-01 2017-02-02 Baruch S. Blumberg Institute Modulation of hepatitis B virus cccDNA transcription
WO2016164619A2 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hbv infection
KR20190057277A (ko) * 2016-06-24 2019-05-28 에모리 유니버시티 B형 간염 바이러스 치료용 포스포아미데이트
WO2019152884A1 (en) * 2018-02-02 2019-08-08 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291534A1 (en) * 2012-11-08 2015-10-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for treating hiv and methods for using the compounds
US20180104325A1 (en) * 2013-07-09 2018-04-19 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling
CN106456615A (zh) * 2014-05-09 2017-02-22 奇尼塔公司 抗病毒化合物、医药组合物及其使用方法
WO2018222910A1 (en) * 2017-05-31 2018-12-06 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN XIAOLAN等: "TLR3 Plays Significant Roles against HBV-Associated HCC", 《GASTROENTEROLOGY RESEARCH AND PRACTICE》, vol. 9, pages 4 *
CHEN XIAO-LONG等: "TLR3 Plays Significant Roles against HBV-Associated HCC", 《GASTROENTEROLOGY RESEARCH AND PRACTICE》, vol. 2015, 31 December 2015 (2015-12-31), pages 1 - 9, XP055818193, DOI: 10.1155/2015/572171 *

Also Published As

Publication number Publication date
WO2021067480A1 (en) 2021-04-08
US20220241314A1 (en) 2022-08-04
EP4037706A4 (en) 2023-09-13
EP4037706A1 (en) 2022-08-10
JP2022550454A (ja) 2022-12-01

Similar Documents

Publication Publication Date Title
CN114502194A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
Sheraz et al. Cellular DNA topoisomerases are required for the synthesis of hepatitis B virus covalently closed circular DNA
Goulet et al. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity
KR102918289B1 (ko) B형 간염 바이러스 (HBV) dsRNA 제제 조성물 및 이의 사용 방법
Metz et al. Identification of type I and type II interferon‐induced effectors controlling hepatitis C virus replication
US11499157B2 (en) Immunomodulatory small hairpin RNA molecules
TWI766831B (zh) 具螯合錯合物及核苷/核苷酸類似物hbv聚合酶抑制劑之組合物及其用於治療hbv感染或hbv/hdv共感染之用途
US20140287023A1 (en) 5'-triphosphate oligoribonucleotides
WO2018209848A1 (zh) 抑制HBV的siRNA分子及其应用
US20150005365A1 (en) Methods for diagnosing and treating learning or mental disorders
Feng et al. IFIT1 expression patterns induced by H9N2 virus and inactivated viral particle in human umbilical vein endothelial cells and bronchus epithelial cells
TW202342064A (zh) 編碼抗融合多肽之環狀多核糖核苷酸
Shimoda et al. Virally encoded interleukin-6 facilitates KSHV replication in monocytes and induction of dysfunctional macrophages
Lei et al. Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV
WO2018168586A1 (ja) ボルナウイルスベクター及びその利用
CN105899238B (zh) 通过调节微RNAmiR-130a、miR-130b、miR-204或miR-1236治疗肝炎病毒感染
EP3395363B1 (en) Compounds for use in treating hbv-and hcv-related conditions
Gaajetaan et al. The type I interferon response during viral infections: a “SWOT” analysis
US20210170034A1 (en) Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-Effect
TW202309282A (zh) 抗病毒核酸
Mustafin et al. COVID-19, retroelements, and aging
Elshina Investigating the mechanisms behind the immunostimulatory activity of influenza A virus RNA polymerase mutations
Eltzschig et al. HIF-dependent induction of alveolar miR-147 dampens SARS-CoV-2 immune evasion
TW202606753A (zh) 一種核酸或核酸組合及其在製備治療乙肝的藥物中的應用
WO2026084025A1 (ja) Ｈｉｖ感染症の治療用医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination